ProCE Banner Activity

BMT CTN 1703: Phase III Trial of PTCy + TAC + MMF vs TAC + MTX for Prevention of GVHD Following Reduced-Intensity Conditioning AlloSCT

Slideset Download
Conference Coverage

Phase III BMT CTN 1703 trial of novel GVHD prophylaxis triplet PTCy + TAC + MMF vs TAC + MTX following reduced-intensity conditioning allogeneic stem cell transplant demonstrated improved GVHD-free relapse-free survival vs TAC + MTX.&nbsp

Released: December 15, 2022

Expiration: December 14, 2023

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

AbbVie

Amgen

AstraZeneca

Epizyme

GSK

Incyte Corporation

Jazz Pharmaceuticals

Karyopharm Therapeutics Inc.

Novartis Pharmaceuticals Corporation

Sanofi

Seagen